Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder.

Autor: Goodyear K; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA.; Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA., Vasaturo-Kolodner TR; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.; Department of Neuroscience, Brown University, Providence, RI, USA., Kenna GA; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA., Swift RM; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA.; Veterans Affairs Medical Center, Providence, RI, USA., Leggio L; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.; Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA.; Veterans Affairs Medical Center, Providence, RI, USA.; Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.; Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.; Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA., Haass-Koffler CL; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA.; Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA.

Publikováno v: The American journal of drug and alcohol abuse [Am J Drug Alcohol Abuse] 2021 Nov 02; Vol. 47 (6), pp. 760-768. Date of Electronic Publication: 2021 Sep 28.

Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder.

Autor: Haass-Koffler CL; From the Department of Psychiatry and Human Behavior (CLH-K, RMS, GAK), Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island.; Department of Behavioral and Social Sciences (CLH-K, VML, LL), Center for Alcohol and Addiction Studies, School of Public Health, Brown University, Providence, Rhode Island.; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section (CLH-K, DP, MRL, LL), National Institute on Drug Abuse Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland., Piacentino D; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section (CLH-K, DP, MRL, LL), National Institute on Drug Abuse Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland.; Center on Compulsive Behaviors (DP, LL), National Institutes of Health, Bethesda, Maryland., Li X; Biostatistics and Clinical Epidemiology Services (XL), National Institutes of Health, Bethesda, Maryland., Long VM; Department of Behavioral and Social Sciences (CLH-K, VML, LL), Center for Alcohol and Addiction Studies, School of Public Health, Brown University, Providence, Rhode Island., Lee MR; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section (CLH-K, DP, MRL, LL), National Institute on Drug Abuse Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland., Swift RM; From the Department of Psychiatry and Human Behavior (CLH-K, RMS, GAK), Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island.; Veterans Affairs Medical Center (RMS), Providence, Rhode Island., Kenna GA; From the Department of Psychiatry and Human Behavior (CLH-K, RMS, GAK), Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island., Leggio L; Department of Behavioral and Social Sciences (CLH-K, VML, LL), Center for Alcohol and Addiction Studies, School of Public Health, Brown University, Providence, Rhode Island.; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section (CLH-K, DP, MRL, LL), National Institute on Drug Abuse Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland.; Center on Compulsive Behaviors (DP, LL), National Institutes of Health, Bethesda, Maryland.; Medication Development Program (LL), National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland.; Division of Addiction Medicine (LL), Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland.; Department of Neuroscience (LL), Georgetown University Medical Center, Washington, District of Columbia.

Publikováno v: Alcoholism, clinical and experimental research [Alcohol Clin Exp Res] 2020 Oct; Vol. 44 (10), pp. 2097-2108. Date of Electronic Publication: 2020 Sep 30.

Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study.

Autor: Haass-Koffler CL; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA. Electronic address: carolina_haass-koffler@brown.edu., Long VM; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA., Farokhnia M; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA. Electronic address: mehdi.farokhnia@nih.gov., Magill M; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA., Kenna GA; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA., Swift RM; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA; Veterans Affairs Medical Center, Providence, RI, USA., Leggio L; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI, USA; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA; Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. Electronic address: lorenzo.leggio@nih.gov.

Publikováno v: Neuropharmacology [Neuropharmacology] 2019 Nov 01; Vol. 158, pp. 107711. Date of Electronic Publication: 2019 Jul 13.

Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study.

Autor: Haass-Koffler CL; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, 121 South Main Street, Providence, RI 02912, USA.; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, 121 South Main Street, Providence, RI 02912, USA.; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, 10 Center Drive (10CRC/15330), Bethesda, MD 20892-1108, USA., Goodyear K; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, 121 South Main Street, Providence, RI 02912, USA.; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, 10 Center Drive (10CRC/15330), Bethesda, MD 20892-1108, USA., Zywiak WH; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, 121 South Main Street, Providence, RI 02912, USA., Leggio L; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, 121 South Main Street, Providence, RI 02912, USA.; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, 10 Center Drive (10CRC/15330), Bethesda, MD 20892-1108, USA., Kenna GA; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, 121 South Main Street, Providence, RI 02912, USA., Swift RM; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, 121 South Main Street, Providence, RI 02912, USA.; Veterans Affairs Medical Center, 830 Chalkstone Ave, Providence, RI 02908, USA.

Publikováno v: Alcohol and alcoholism (Oxford, Oxfordshire) [Alcohol Alcohol] 2018 May 01; Vol. 53 (3), pp. 268-276.

Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis.

Autor: Kotake K; Department of Pharmacy, Okayama Saiseikai General Hospital, Okayama, Japan.; Scientific Research Works Peer Support Group (SRWS-PSG), Osaka, Japan., Hosokawa T; Department of Psychiatry, Zikei Hospital/Zikei Institute of Psychiatry, Okayama, Japan., Tanaka M; Department of Psychiatry, Zikei Hospital/Zikei Institute of Psychiatry, Okayama, Japan., So R; Scientific Research Works Peer Support Group (SRWS-PSG), Osaka, Japan.; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan., Banno M; Scientific Research Works Peer Support Group (SRWS-PSG), Osaka, Japan.; Department of Psychiatry, Seichiryo Hospital, Nagoya, Japan.; Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan., Kataoka Y; Scientific Research Works Peer Support Group (SRWS-PSG), Osaka, Japan.; Department of Internal Medicine, Kyoto Min-iren Asukai Hospital, Kyoto, Japan.; Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.; Section of Clinical Epidemiology, Department of Community Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan., Shiroshita A; Scientific Research Works Peer Support Group (SRWS-PSG), Osaka, Japan.; Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA., Hashimoto Y; Faculty of Clinical Pharmacy, Kobe Gakuin University, Kobe, Japan.

Publikováno v: Addiction (Abingdon, England) [Addiction] 2024 May; Vol. 119 (5), pp. 815-832. Date of Electronic Publication: 2024 Jan 03.